Gut colonization with multidrug resistant organisms in the intensive care unit: a systematic review and meta-analysis.

Autor: Heath MR; Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA., Fan W; Mailman School of Public Health, Columbia University, New York, NY, USA., Leu CS; Mailman School of Public Health, Columbia University, New York, NY, USA., Gomez-Simmonds A; Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA., Lodise T; Albany College of Pharmacy and Health Sciences, Albany, NY, USA., Freedberg DE; Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA. def2004@cumc.columbia.edu.
Jazyk: angličtina
Zdroj: Critical care (London, England) [Crit Care] 2024 Jun 28; Vol. 28 (1), pp. 211. Date of Electronic Publication: 2024 Jun 28.
DOI: 10.1186/s13054-024-04999-9
Abstrakt: Background: Gut colonization with multidrug-resistant organisms (MDRO) frequently precedes infection among patients in the intensive care unit (ICU), although the dynamics of colonization are not completely understood. We performed a systematic review and meta-analysis of ICU studies which described the cumulative incidence and rates of MDRO gut acquisition.
Methods: We systematically searched PubMed, Embase, and Web of Science for studies published from 2010 to 2023 reporting on gut acquisition of MDRO in the ICU. MDRO were defined as multidrug resistant non-Pseudomonas Gram-negative bacteria (NP-GN), Pseudomonas spp., and vancomycin-resistant Enterococcus (VRE). We included observational studies which obtained perianal or rectal swabs at ICU admission (within 48 h) and at one or more subsequent timepoints. Our primary outcome was the incidence rate of gut acquisition of MDRO, defined as any MDRO newly detected after ICU admission (i.e., not present at baseline) for all patient-time at risk. The study was registered with PROSPERO, CRD42023481569.
Results: Of 482 studies initially identified, 14 studies with 37,305 patients met criteria for inclusion. The pooled incidence of gut acquisition of MDRO during ICU hospitalization was 5% (range: 1-43%) with a pooled incidence rate of 12.2 (95% CI 8.1-18.6) per 1000 patient-days. Median time to acquisition ranged from 4 to 26 days after ICU admission. Results were similar for NP-GN and Pseudomonas spp., with insufficient data to assess VRE. Among six studies which provided sufficient data to perform curve fitting, there was a quasi-linear increase in gut MDRO colonization of 1.41% per day which was stable through 30 days of ICU hospitalization (R 2  = 0.50, p < 0.01).
Conclusions: Acquisition of gut MDRO was common in the ICU and increases with days spent in ICU through 30 days of follow-up. These data may guide future interventions seeking to prevent gut acquisition of MDRO in the ICU.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: